Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: PaulW who wrote (4274)	3/14/2000 9:09:00 AM
From: Biomaven	Respond to of 10280

Paul, I don't think the once-a-week Prozac will have that much impact on the demand for Prozac II. The new drug is targeted at people who are already on Prozac and want more convenience. It would have an even longer wash-out period than regular Prozac, and so would not be attractive for new patients. Basically Lilly is trying to defend its Prozac franchise against the other competitors and eventual generics, and so they are looking for additional formulations that may be hard to imitate. If Prozac II turns out to have advantages over and above a shorter wash-out period, then Lilly may eventually produce a once-a-week formulation of Prozac II as well. Peter